Brolucizumab: Will it Make a Differance

Related

• 

  Phase IIIb TALON study of brolucizumab versus aflibercept in a matched treat-and-extend regimen to treat neovascular AMD: 32-week primary outcomes

  Carl D. Regillo, MD

  Annual Meeting Talks

  2022

• 

  Abicipar Pegol Phase 3 AMD Studies

  Pravin U. Dugel, MD

  Updates from the Field

  2017

• 

  Expert Panel: PVR

  Christina Y Weng, MD, MBA, FASRS

  Lejla Vajzovic, MD, FASRS

  Isabela Martins Melo, MD

  Sarah Syeda, MD

  Prashant Keshao Bawankule, M.S.

  Leo A. Kim, MD, PhD

  Annual Meeting Talks

  2024